Xcorporeal (OTCMKTS:XCRP) vs. Mesa Laboratories (NASDAQ:MLAB) Financial Comparison

Xcorporeal (OTCMKTS:XCRP) and Mesa Laboratories (NASDAQ:MLAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Valuation and Earnings

This table compares Xcorporeal and Mesa Laboratories”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xcorporeal	N/A	N/A	N/A	N/A	N/A
Mesa Laboratories	$249.13 million	2.30	$6.71 million	$1.20	86.58

Mesa Laboratories has higher revenue and earnings than Xcorporeal.

Profitability

This table compares Xcorporeal and Mesa Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xcorporeal	N/A	N/A	N/A
Mesa Laboratories	2.69%	20.96%	8.78%

Analyst Recommendations

This is a summary of recent ratings and price targets for Xcorporeal and Mesa Laboratories, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xcorporeal	0	0	0	0	0.00
Mesa Laboratories	1	2	0	0	1.67

Mesa Laboratories has a consensus target price of $94.00, suggesting a potential downside of 9.52%. Given Xcorporeal’s higher probable upside, research analysts plainly believe Xcorporeal is more favorable than Mesa Laboratories.

Insider & Institutional Ownership

90.6% of Mesa Laboratories shares are owned by institutional investors. 4.9% of Mesa Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Mesa Laboratories beats Xcorporeal on 7 of the 8 factors compared between the two stocks.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.

About Mesa Laboratories

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.